Furthermore, whereas administration of this anti-IL-2/IL-2 complex altered the ratio of Tconvs to Tregs in favour of Tregs in secondary lymphoid tissues, the ratio of Tconvs to Tregs in the tumor did not change (Figure 3C). Here, IL2 is linked to neoplasm.